Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • CDSCO tightens safety...

    CDSCO tightens safety and labelling rules for ISOTRETINOIN,prescription of dermatologist mandatory

    Farhat NasimWritten by Farhat Nasim Published On 2018-12-21T13:06:28+05:30  |  Updated On 16 Aug 2021 6:00 PM IST

    In light of concerns raised regarding Isotretinoin, the matter has been examined by CDSCO in consultation with the Subject Expert Committee (Dermatology and Allergy) in its meeting held on July 26, the communique stated.





    New Delhi: The Drug Controller General of India (DCGI) has asked drugs controllers in all states and Union Territories to ensure that Isotretinoin, used to treat severe cystic acne, is sold by retailers on prescription of dermatologists only. The Central Drugs Standard Control Organization (CDSCO), in a communique, said the packets containing the drug should carry a box warning stating 'this medicine may cause severe birth defects; you must not take this medicine if you are pregnant or may likely become pregnant during treatment' and 'you should also avoid pregnancy for six months after stopping the treatment'.


    The patients should also sign a consent form before "undertaking the treatment of Isotretinoin" as already stipulated.



    The communique stated the conditions should be followed during manufacture, sale and distribution of the drug as already stipulated by the CDSCO at the time of approval of the oral drug.

    Isotretinoin capsule 10mg/ 20mg was approved by CDSCO on June 21, 2002, for treatment of cystic and conglobate acne, severe nodular acne unresponsive to antibiotic therapy, with various conditions.

    In light of concerns raised regarding Isotretinoin, the matter has been examined by CDSCO in consultation with the Subject Expert Committee (Dermatology and Allergy) in its meeting held on July 26, the communique stated.

    The Subject Expert Committee deliberated the matter in detail and opined that the drug has a favourable risk-benefit profile for the indications approved in the country. However, some conditions should be followed during manufacture, sale and distribution of the drug as already stipulated by CDSCO at the time of its approval, according to the communique.

    "The committee also recommended that the manufacturers should provide package insert along with their product which should be in major vernacular languages. Retail chemists should maintain the details of the retail sale of the drug which should be strictly on the prescription of Dermatologist only," it stated.




    Read Also: Asbestos scare: CDSCO draws samples of J&J baby powder from HP plant
    antibiotic therapyCDSCOCentral Drugs Standard Control OrganizationChemistconglobate acnecystic acneDCGIdermatologistsDermatology and AllergyDrugs Controller General Indiaisotretinoinnodular acnePatientpharmacistUnion Health Ministry
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok